Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, and Estrogen and related hormone effects.
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials
Data from SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials
Data from SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
23P Clinical, pathological and gene expression features of HER2-low breast cancer
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.
Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer